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We systematically reviewed the literature on the accuracy of new technologies proposed for breast cancer screening. Four potential
tests were identified (ultrasound, magnetic resonance imaging (MRI), full-field digital mammography (FFDM), and computer-aided
detection (CAD)) for which primary studies met quality and applicability criteria and provided adequate data on test accuracy. These
technologies have been assessed in cross-sectional studies of test accuracy where the new test is compared to mammography.
Ultrasound, used as an adjunct to mammography in women with radiologically dense breasts, detects additional cancers and causes
additional false positives. Magnetic resonance imaging may have a better sensitivity (but lower specificity) than mammography in
selected high-risk women, but studies of this technology included small number of cancers. Computer-aided detection may enhance
the sensitivity of mammography and warrants further evaluation in large prospective trials. One study of FFDM suggests that it may
identify some cancers not identified on conventional mammography and may result in a lower recall rate. The evidence is currently
insufficient to support the use of any of these new technologies in population screening, but would support further evaluation.
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Despite recent controversy surrounding the efficacy of mammo-
graphic screening, it remains the only screening test for breast
cancer that has been extensively evaluated in randomised
controlled trials (RCTs) and shown to reduce breast cancer
mortality (IARC, 2002; Nystrom et al, 2002). Since evidence exists
that early detection reduces mortality from breast cancer, it is
reasonable to evaluate a new screening test by assessing its effect
on early detection of breast cancer. While RCTs examining
mortality as an outcome are the gold standard, studies assessing
new tests are commonly evaluated using surrogate measures as
indicators of early breast cancer detection. These surrogate
measures may be measurable at the time of screening or require
follow-up. Immediate indicators include the cancer detection rate
and the size, stage, and nodal status of cancers detected. The
measure requiring follow-up is the interval cancer rate. Ascertain-
ment of interval breast cancers poses a number of challenges that
include identification (requiring linkage to cancer registries),
standardisation, and validation of review and categorisation
methods, as well as access to the films taken at diagnosis.
Assessing whether tests differ in their interval cancer rate is best
assessed by randomising people to the different tests. In designs in
which women are assessed by both tests, women in whom cancers
are detected by either test would obviously be identified and
treated; interval cancers that arise thereafter would be those
missed by both tests. To assess whether interval cancer rates differ
between the tests is therefore best assessed by randomising women
to the different tests. However, all of the immediately measurable
surrogates can be assessed in cross-sectional analytic studies of
people in whom both of the different tests have been carried out.
New screening methods can be evaluated relative to the proven
screening test (screening mammography being the comparator test
for breast cancer) as a replacement for the comparator or as an
incremental (additional) method, whereby the new test would only
be carried out in those where the comparator test is negative. To
allow estimation of both replacement and incremental accuracy,
the basic study design is to screen women independently by both
mammography and the new test, and assess how many cancers and
false positives are detected by one test and not the other. If the
objective is to assess incremental accuracy only (additional cancers
detected, as well as additional false positives caused by use of the
new test), this can be carried out by re-examining only those who
were negative on mammography and can be carried out with or
without knowledge of the mammography result.
Over the past two decades numerous breast imaging tests have
been evaluated and used mainly as adjunct diagnostic methods to
mammography, and some have been proposed as possible
screening tests. Some of these tests, such as computer-aided
detection (CAD), are rapidly evolving and continue to be
evaluated. Other tests, primarily ultrasound, have an established
role in the investigation of symptomatic women and in the
evaluation of screen-detected findings. In this paper, we present a
systematic review of published work on the accuracy of
new technologies that have been proposed for breast cancer
screening.
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To avoid bias, we systematically reviewed the literature using
methods that ensure all relevant studies were identified (Appendix
A, literature search methods). The quality and applicability of
studies were assessed before their findings were examined
(Glasziou et al, 2001) (Appendix B, strategy for selection of
eligible studies). As both sensitivity and specificity are important
in the screening context, our selection criteria required studies to
have reported data on both sensitivity and specificity (Appendix
B). To ensure the applicability of the results to screening, the
studies had to have been carried out on women eligible for
screening. Studies on symptomatic women cannot be used to infer
the accuracy of a new technique for screening, because the
objective of testing is different. In clinical settings, the objective is
to determine whether an identified clinical abnormality is cancer.
In screening, it is to perceive abnormalities that may be found on
further testing to be early cancers. Furthermore, the spectrum of
disease usually differs in that cancers which present clinically
would be expected to be larger and more advanced.
Papers were therefore included only if they evaluated new tests
in asymptomatic women, including populations considered at
higher risk for breast cancer because of genetic predisposition or
those in whom mammography may be less accurate because they
are younger or have radiologically dense breast tissue. Very few
studies fulfilled these criteria. The remainder of the papers were
review articles, were concerned with the development of the test, or
evaluated the use of the test in individual cases or as a diagnostic
tool in women with a clinically or mammographically detected
breast abnormality. Papers on screening were excluded if
important technological changes made them no longer relevant.
On these grounds, articles on thermography before 1988 were
excluded, as were papers on ultrasonography with water baths or
frequency probes with a resolution less than 7.5mHz. We also
excluded studies that compared the proposed technology with an
unproven screening method, and on this basis one otherwise
eligible study of positron emission tomography was excluded
(Yasuda et al, 2000). Although studies included used histological
diagnosis to verify outcomes, very few papers reported data on
interval cancers. However, this does not invalidate comparative
studies in which both tests (new technology and mammography)
are performed in all women since interval cancers will have been
missed by both tests. Our review was concerned with the accuracy
of new tests or new technologies associated with mammography,
and did not include a cost evaluation.
RESULTS
No eligible papers were found for CT scanning, magnetic
resonance spectroscopy (MRS), scintimammography, electrical
impedance, infrared spectroscopy, light scanning, positron emis-
sion tomography, or thermography. Eligible studies were identified
for ultrasound (Kolb et al, 1998; Buchberger et al, 1999; O’Driscol
et al, 2001; Warner et al, 2001; Hou et al, 2002) magnetic resonance
imaging (MRI) (Kuhl et al, 2000; Tilanus-Linthorst et al, 2000a,b;
Stoutjesdijk et al, 2001; Warner et al, 2001), CAD (te Brake et al,
1998; Burhenne et al, 2000; Birdwell et al, 2001; Freer and Ulissey,
2001), and full-field digital mammography (FFDM) (Lewin et al,
2001, 2002). For ultrasound, MRI, and CAD, findings are
summarised in Tables 1–3. There was no evidence originating
from RCTs.
Table 1 US (table summarises published studies on US in screening, including study design, quality features, and results)
Reference
Objective
a;
comparator
Population (mean
age in years)
Test evaluated
1 – In consecutive
screenees
2 – Independent of
comparator
No. of breast
cancers (total
sample size) TPR or sensitivity
FPR (based on solid
lesions for US)
Kolb et al (1998,
2002)
I only; M+CBE
Views: ND
Reader: 1–2
Dense breasts and
normal M+CBE (54.7)
1–Yes
2–ND for all subjects
(Yes for M-negative/
US-positive group)
145; 124
b (13547
screens in 5418
women)
Incremental TPR of
US¼25.5%
Incremental FPR of
US¼2.4% (biopsy) and
5.3% (biopsy or follow-up)
Hou et al (2002) I+R; M+CBE
Views: 2
Reader: 1
‘High-risk’ female relatives
of breast cancer patients
(48.6)
1–ND
2–ND
21 (935) US: 90.4%
M: 52.4%
CBE: 33.3%
Incremental TPR of
US¼33.3%
For abnormal screen –
biopsy
US: 12.9–2.5%
M: 6.0–1.6%
CBE: 1.8–1.2%
Incremental FPR of
US¼6.9%
O’Driscoll et al
(2001)
I + R; M
Views and
Reader: ND
Moderate-risk (family
history) through clinical
genetics unit (42)
1–Yes
2–Yes
2
b (150) US: 50%
M: 50%
US: 6.0%
M: 0.7% (core biopsy rate)
Warner et al
(2001)
I+R; M+CBE
Views: 2
Reader: 1
High-risk, BRCA mutation
or several family
members (43)
1–ND
2–YES
6; 5
b (186) US: 60%
M: 40%
CBE: 20%
Incremental TPR of
US¼0%
US: 7%
M: 1%
CBE: 1%
Buchberger et al
(1999)
I+R; M
Reader: 1
Dense breasts and
normal CBE (49)
1–ND
2–ND
182; 130
b (8970) US: 99% (invasive), 46%
(DCIS)
M: 73% (invasive), 90%
(DCIS)
US: 4% (biopsy)
M: ND
US¼ultrasound; M¼mammography; CBE¼clinical breast examination; ND¼not described or unclear from paper; TPR¼true-positive rate; FPR¼false-positive rate.
DCIS¼ductal carcinoma in situ.
aObjective attainable in using the test: R¼replacement for comparator, I¼incremental to comparator; Views¼number of mammography views
per breast, Reader¼number of mammography readers.
bNumber of cancers reported to be invasive cancers.
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women who have mammographically dense breast tissue or are
considered to be at elevated risk of breast cancer. The five studies
included over 350 cancers. The results suggest that ultrasound may
be more sensitive but less specific than mammography in these
women. Ultrasound used as an additional test to mammography
detects additional cancers, but also increases the false-positive
rate.
Magnetic resonance imaging (Table 2) has been examined in
four recent studies, which evaluated the test in women at high risk
of cancer (usually on the basis of genetic mutations or a family
history of breast cancer). In all studies, the technology was
contrast-enhanced MRI and all studies used a dedicated breast
coil. There were less than 40 cancers in all studies combined. The
results suggest that MRI is more sensitive than mammography in
selected populations, but may also have a lower specificity. There
are currently several trials being conducted in the UK, Europe, and
the USA to assess the role of MRI in breast screening (UK MRI
Breast Screening Study Advisory Group, 2000), (http://www.acri-
n.org/current_protocols.html. Accessed 5/12/03).
Computer-aided detection is essentially a tool to ‘prompt’ the
radiologist to look at potential abnormalities on digitised
mammograms and is complementary technology to mammogra-
phy. In the screening context, it is potentially equal to another
‘read’ (that is, one reader plus CAD may potentially replace two
readers). CAD (Table 3) has been assessed in several studies with
over 650 cancers. However, only one of these studies was
prospectively conducted (Freer and Ulissey, 2001). All of the
studies examined the incremental value of CAD and showed
improved sensitivity; the evidence on specificity is conflicting. It is
not clear to what extent the improvement compares to other
manoeuvres, such as having a second film reader.
Table 2 MRI (table summarises published studies on MRI in screening, including study design, quality features, and results)
Reference
Objective
a;
comparator
Population (mean
age in years)
Test evaluated
1 – In consecutive
screenees
2 – Independent of
comparator
No. of breast
cancers (total
sample size) TPR or sensitivity
FPR (%
requiring
biopsy)
Warner et al (2001) I+R; M+CBE+US
Views: 2
Reader: 1
High risk, BRCA or
several family members
(43)
1–N D
2 – Yes
6
b (196) M: 33%
CBE: 33%
US: 60%
MRI: 100%
Incremental TPR of MRI¼33%
M: 1%
CBE: 1%
US: 7%
MRI: 9%
Stoutjesdijk et al (2001) I+R; M
Views: 2
Reader: 1
Breast cancer lifetime
risk 415% (40)
1–N o
2 – Yes
12 (259 tests on
166 women)
M: 46%
MRI: 100%
Incremental TPR of MRI¼54%
M: 4%
MRI: 7%
Tilanus-Linthorst et al
(2000a,b)
I only; M+CBE
Views: 1–2
Reader: 2
High risk (425%) and
450% breast density
(41.5)
1 – Yes
2–N D
ND–probably
between 3–10
(109)
Two cancers detected by MRI
but not by M+CBE
ND
Kuhl et al (2000) I+R; M+US
Views: 2
Reader: 2
High risk of familial
breast cancer (39)
1–N o
2 – Yes
9 (105) M: 33%
US: 33%
M+US: 44%
MRI: 100%
M: 7%
US: 20%
MRI: 5%
MRI¼magnetic resonance imaging; M¼mammography; CBE¼clinical breast examination; US¼ultrasound; ND¼not described or unclear from paper; TPR¼true-positive
rate; FPR¼false-positive rate.
aObjective attainable in using the test: R¼replacement for comparator; I¼incremental to comparator; Views¼number of mammography views
per breast, Reader¼number of mammography readers.
bNumber of cancers reported to be invasive cancers.
Table 3 CAD (table summarises published studies on CAD in screening, including study design, quality features, and results)
Reference
Objective
a;
comparator
Population (mean
age in years)
Test evaluated
1 – In consecutive
screenees
2 – Independent of
comparator
No. of breast
cancers
(total sample
size) TPR or Sensitivity
FPR (based on
recall rate)
Birdwell et al (2001)
Burhenne et al (2000)
I only; M
Views: 2
Reader: 1
Average-risk.
CAD assessed on prior
M in women later
found to have breast
cancer
1–No
2–No (yes for non-
cancers)
542 (14500) M: 79%
Incremental TPR of
CAD¼16%
FPR from before
after study
M: 8.3%
CAD: 7.6%
Freer and Ulissey (2001) I only; M
Views: 2
Reader: 1
Average risk 1–Yes
2–No
49 (12860) M: 83.7%
Incremental TPR of
CAD¼16.3%
M: 6.5%
CAD: 7.7%
Incremental FPR of
CAD¼1.2%
Te Brake et al (1998) I only; M
Views: 1
Reader: 2
Women subsequently
shown to have breast
cancer
1–No
2–No
65 (207) Incremental true positives
reported (difficult to quantify)
Incremental false
positives reported
(difficult to
quantify)
CAD¼computer-aided diagnosis; M¼mammography; ND¼not described or unclear from paper; TPR¼true-positive rate; FPR¼false-positive rate.
aObjective attainable in
using the test: R¼replacement for comparator, I¼incremental to comparator; Views¼number of mammography views per breast, Reader¼number of mammography
readers.
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technology that uses a digital receptor instead of the conventional
screen film, resulting in a computer-generated image. Full-field
digital mammography has the potential to improve image
resolution and image processing and display techniques relative
to conventional mammography. Full-field digital mammography
has been examined in one study, which screened 4489 average-risk
women 40 years and older (Lewin et al, 2001, 2002). In this study,
42 invasive cancers were detected (and four interval cancers were
identified at 12 months). Full-field digital mammography was
found to have a lower overall sensitivity (64.3%) than conventional
mammography (78.6%). However, despite having a lower overall
sensitivity than conventional mammography, FFDM does result in
an incremental gain in sensitivity of 21.4% (that is, it will identify
additional cancers that are not identified on conventional
mammography). Full-field digital mammography was reported to
have a recall rate of 11.8%, which was significantly lower (Po
0.001) than the recall rate of conventional mammography (14.9%).
DISCUSSION
New technologies proposed for breast cancer detection have not
been evaluated in RCTs that examine the reduction of the interval
cancer rate as indicators of early breast cancer detection. These
new technologies have been assessed in cross-sectional analytic
studies of test sensitivity and specificity, where the new test is
compared to mammography. None of the tests evaluated
consistently showed sufficient accuracy in high-quality studies to
support their use in population screening. The conduct and
reporting of the studies were limited, and the populations were
generally too small to allow adequate precision in critical
measures, such as test sensitivity. Most of the eligible studies
identified in our review did not provide data on interval cancers,
and although this is required for an estimation of test sensitivity, it
does not invalidate data presented on the difference in sensitivity
of the two tests since interval cancers will have been missed by
both the new and the comparator test (Chock et al, 1997).
Ultrasound may increase the sensitivity of screening if used as
an adjunct to mammography for women shown to have
radiologically dense breasts, but is likely to increase substantially
the number of women requiring biopsy for benign findings. The
data from the ultrasound studies are far from conclusive, but does
suggest that the potential for ultrasound to replace mammography
in screening selected populations warrants further investigation. In
addition, ultrasound is highly operator dependent, and the
findings from the reported studies may not be applicable in a
broader screening context. Magnetic resonance imaging has not
been evaluated as a screening test in unselected populations, and
its potential role in screening (if any) is in women at high risk of
breast cancer.
Based on a limited number of studies, FFDM and CAD show an
incremental improvement in sensitivity relative to conventional
mammography. However, incremental improvement in sensitivity
will not necessarily translate into an absolute benefit, since the new
technology may be selectively detecting cancers that are biologi-
cally inconsequential. Both FFDM and CAD are currently being
evaluated in ongoing studies. Future studies of these two
technologies, in particular, should be supported using prospective
designs, large samples, and preferably randomised trials using the
difference in interval cancers as one of the outcome measures.
Studies that assess new technology before its widespread
introduction should be carried out in consecutive women eligible
for screening. Cancer is likely to be detected in only a few percent
of women screened. Therefore, the confidence intervals for
estimates of the sensitivity of new tests, or for differences in
sensitivity between new and existing tests, will require screening
tens of thousands of women, to detect at least 100 cancers. Future
studies should therefore be designed to have adequate sample
sizes, for example as is being carried out in the digital
mammography screening trial, which aims to recruit 49500
asymptomatic women presenting for screening (http://www.can-
cer.gov/dmist and http://www.acrin.org/current_protocols.html
Accessed 5/12/03). Studies of new tests in any context, should
conform to high standards of conduct and reporting (Bossuyt et al,
2003), should clarify whether the new test is being evaluated as a
replacement or as an additional test, and should use the
appropriate study design to assess the intended use of the test.
Studies evaluating new technologies in breast cancer screening,
relative to mammography, should provide information on the
number of views and the number of readers for both the new
technology and mammography, and should assess the effect of
increasing the number of views or readers.
Although some of the proposed new screening tests show
promise, there is a need for larger and better quality of studies of
new technology, starting soon after it is introduced to allow
concurrent evaluation and implementation (Hunink and Krestin,
2002). As new technology often changes rapidly, it might seem
appropriate to leave evaluation until the new technology is ‘stable’.
However, methods can be used to assess changes and develop-
ments of new technologies as part of the study design to allow early
evaluation of new technologies (Hunink and Krestin, 2002).
Studies that compare two screening tests or technologies in the
same women can provide data on whether new tests do better than
the existing ones in detecting more cancers. Before widespread
implementation, those tests that show promise in cross-sectional
analytic studies should then be evaluated in large randomised
trials to ensure that they also reduce the interval cancer rate.
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Appendix A
Literature search
MEDLINE was searched from 1966 to December 2002 using the
following methods: explode breast neoplasms (all subheadings);
explode sensitivity and specificity (all subheadings); explode mass
screening (all subheadings); combine previous steps using the
Boolean term ‘or’; search term(s) for the specific test of interest
and combining using the Boolean term ‘or; combine all previous
steps using the Boolean term ‘and’. Searching for specific tests
using search term(s) included: CAD; CT scan (tomography);
electrical impedance; FFDM; digital mammography; scintimam-
mography (Tc 99m sestamibi, mammoscintigraphy); MRI; MRS;
optical mammography (transillumination); PET; spectroscopy;
thermography; and ultrasound (sonography).
The search was extended by examining references given in
relevant primary studies and review articles, contact with content
experts, and targeted further MEDLINE searches, for example on
authors of earlier studies. MEDLINE searching identified 649
papers, and our overall search identified more than 1750 papers.
Appendix B
Strategy for selection of eligible studies
The titles and abstracts of all papers were evaluated by one author
(CVV) and those possibly relevant were then assessed for final
selection by one of the two reviewing authors (reviewing authors:
LI or NH). Studies that included the largest number of cancers or
those for which it was difficult to extract the information were in
addition independently assessed by one of the two reviewers (LI or
NH), and differences between the reviewers were resolved by
discussion and consensus.
The following information was examined to determine eligible
studies, with assessment of quality and applicability criteria prior
to the extraction of study results:
a. Quality (consecutively attending screenees; screening tests
applied to all participants; screening tests assessed independent
of each other).
b. Objective and applicability (Was the study designed to
explore the value of the new screening test as a replacement
test or to assess its incremental accuracy to existing screening
test? Was the study restricted to special groups such as women
with high breast cancer risk or dense breast tissue on
mammography? To what was the replacement or incremental
value of the new test being compared, including descriptive
information on number of mammography views and number of
readers?).
c. Results (number of cancers and total population size;
true-positive rate (TPR or sensitivity) and false-positive
rate (FPR, 1 – specificity), or as a proxy the test positivity
rate or biopsy rate) in the overall screened population. Studies
were excluded if they did not report any measure of TPR or
FPR.
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